Journal of Clinical Pathology 2008;61:677-680
SHORT REPORTS
FIP1L1–PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement
1 Department of Haematology, Newcastle Hospitals Trust, Newcastle upon Tyne, UK
2 Regional Neurosciences Unit, Newcastle Hospitals Trust, Newcastle upon Tyne, UK
3 NHS Northern Genetics Service, Newcastle upon Tyne, UK
4 Department of Histopathology, Newcastle Hospitals Trust, Newcastle upon Tyne, UK
5 Department of Haematology, City Hospitals Sunderland Trust, Sunderland, UK
Correspondence to:
Dr Chris Williams, Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; cdwilliams26{at}blueyonder.co.uk
Interstitial deletion involving chromosome 4q12 generates the novel tyrosine kinase fusion protein encoded by FIP1L1–PDGFRA, which is present in many patients previously labelled as having hypereosinophilic syndrome, initially reported in 2003. Reports in recent literature document excellent clinical and molecular response to the tyrosine kinase inhibitor imatinib (Glivec). This report describes the case of a 58-year-old lady, diagnosed with FIP1L1–PDGFRA positive hypereosinophilic disorder, who subsequently developed symptoms related to an intracranial lesion. Biopsy and molecular genetic studies confirmed a diffuse infiltrative lesion, with evidence of FIP1L1–PDGFRA gene fusion. Initiation of imatinib treatment led to impressive clinical and radiological response.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
